July 13, 2018 10:09 AM EDT
Peer Review

George Golumbeski's first stop out of Cel­gene: Grail; Roivant taps Genen­tech vet Myr­tle Pot­ter for op­er­a­tions role

Amber Tong

→ Three months af­ter qui­et­ly slip­ping out the back door at Cel­gene, George Golumbes­ki has tak­en up the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

No­vo Nordisk is feel­ing the com­pe­ti­tion from com­pound­ed GLP-1s, ex­ec says

Ku­ra's AML drug pass­es key study in ad­vanced pa­tients, plans next steps with FDA and new­ly di­ag­nosed stud­ies

Small per­son­al­ized vac­cine tri­al sees progress in late-stage kid­ney can­cer

Am­gen an­nounces hold on Phase 1 obe­si­ty can­di­date, pipeline cuts

Eye­Point shares more mid-stage da­ta for ther­a­py try­ing to com­pete with Re­gen­eron's Eylea

Pfiz­er says it has at least $10B avail­able for deals in 2025, with a fo­cus on pipeline

A service from the Financial Times